170 related articles for article (PubMed ID: 12120879)
1. Emerging antimicrobial resistances among Proteus mirabilis in Europe: report from the MYSTIC Program (1997-2001). Meropenem Yearly Susceptibility Test Information Collection.
Mutnick AH; Turner PJ; Jones RN
J Chemother; 2002 Jun; 14(3):253-8. PubMed ID: 12120879
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA).
Rhomberg PR; Fritsche TR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2006 Sep; 56(1):57-62. PubMed ID: 16631338
[TBL] [Abstract][Full Text] [Related]
3. Susceptibility of bacterial isolates from Turkey--a report from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program.
Eraksoy H; Basustaoglu A; Korten V; Kurt H; Ozturk R; Ulusoy S; Yaman A; Yuce A; Zarakolu P;
J Chemother; 2007 Dec; 19(6):650-7. PubMed ID: 18230545
[TBL] [Abstract][Full Text] [Related]
4. Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum β-lactamase-producing Proteus mirabilis.
Tsai HY; Chen YH; Tang HJ; Huang CC; Liao CH; Chu FY; Chuang YC; Sheng WH; Ko WC; Hsueh PR
Diagn Microbiol Infect Dis; 2014 Nov; 80(3):222-6. PubMed ID: 25139843
[TBL] [Abstract][Full Text] [Related]
5. Results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: report of the 2001 data from 15 United States medical centres.
Rhomberg PR; Jones RN; Sader HS;
Int J Antimicrob Agents; 2004 Jan; 23(1):52-9. PubMed ID: 14732314
[TBL] [Abstract][Full Text] [Related]
6. MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates.
Turner PJ
Diagn Microbiol Infect Dis; 2009 Feb; 63(2):217-22. PubMed ID: 19070453
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program.
Sun HK; Kuti JL; Nicolau DP
Crit Care Med; 2005 Oct; 33(10):2222-7. PubMed ID: 16215374
[TBL] [Abstract][Full Text] [Related]
8. Comparative antimicrobial potency of meropenem tested against Gram-negative bacilli: report from the MYSTIC surveillance program in the United States (2004).
Rhomberg PR; Fritsche TR; Sader HS; Jones RN
J Chemother; 2005 Oct; 17(5):459-69. PubMed ID: 16323433
[TBL] [Abstract][Full Text] [Related]
9. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005).
Rhomberg PR; Jones RN
Diagn Microbiol Infect Dis; 2007 Feb; 57(2):207-15. PubMed ID: 16949243
[TBL] [Abstract][Full Text] [Related]
10. Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results.
Turner PJ
Diagn Microbiol Infect Dis; 2008 Feb; 60(2):185-92. PubMed ID: 17945455
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: report from the MYSTIC Program (2002) in North America.
Rhomberg PR; Jones RN;
Diagn Microbiol Infect Dis; 2003 Sep; 47(1):365-72. PubMed ID: 12967752
[TBL] [Abstract][Full Text] [Related]
12. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from Europe: comparison of antibiotic susceptibilities between countries and centre types. MYSTIC Study Group (European centres only).
Goossens H
J Antimicrob Chemother; 2000 Sep; 46 Suppl T2():39-52. PubMed ID: 11065147
[TBL] [Abstract][Full Text] [Related]
13. Antipseudomonal activity of piperacillin/tazobactam: more than a decade of experience from the SENTRY Antimicrobial Surveillance Program (1997-2007).
Jones RN; Stilwell MG; Rhomberg PR; Sader HS
Diagn Microbiol Infect Dis; 2009 Nov; 65(3):331-4. PubMed ID: 19822273
[TBL] [Abstract][Full Text] [Related]
14. Properties of multidrug-resistant, ESBL-producing Proteus mirabilis isolates and possible role of beta-lactam/beta-lactamase inhibitor combinations.
Luzzaro F; Perilli M; Amicosante G; Lombardi G; Belloni R; Zollo A; Bianchi C; Toniolo A
Int J Antimicrob Agents; 2001 Feb; 17(2):131-5. PubMed ID: 11165117
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme: report of year five (2003).
Rhomberg PR; Jones RN; Sader HS; Fritsche TR;
Diagn Microbiol Infect Dis; 2004 Aug; 49(4):273-81. PubMed ID: 15313533
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of a modified double-disc synergy test for detection of extended spectrum beta-lactamases in AMPC beta-lactamase-producing proteus mirabilis.
Khan MK; Thukral SS; Gaind R
Indian J Med Microbiol; 2008; 26(1):58-61. PubMed ID: 18227600
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program.
Ong CT; Kuti JL; Nicolau DP;
Surg Infect (Larchmt); 2005; 6(4):419-26. PubMed ID: 16433606
[TBL] [Abstract][Full Text] [Related]
18. Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008).
Rhomberg PR; Jones RN
Diagn Microbiol Infect Dis; 2009 Dec; 65(4):414-26. PubMed ID: 19833471
[TBL] [Abstract][Full Text] [Related]
19. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection): a global overview.
Turner PJ
J Antimicrob Chemother; 2000 Sep; 46 Suppl T2():9-23. PubMed ID: 11065145
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial susceptibilities of Proteus mirabilis: a longitudinal nationwide study from the Taiwan surveillance of antimicrobial resistance (TSAR) program.
Wang JT; Chen PC; Chang SC; Shiau YR; Wang HY; Lai JF; Huang IW; Tan MC; Lauderdale TL;
BMC Infect Dis; 2014 Sep; 14():486. PubMed ID: 25192738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]